GENVEC, INC.

Basic Information

910 CLOPPER RD STE 220N
GAITHERSBURG, MD, 20878-1353

http://www.genvec.com

Company Profile

GenVec is a clinical-stage gene delivery company focused on developing a pipeline of cutting-edge therapeutics and vaccines using its proprietary AdenoVerse™ gene delivery platform. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec’s lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to its internal and partnered pipeline, the company is also focused on opportunities to license its proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry.

Additional Details

Field Value
DUNS: 806729547
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 15


  1. Adenovirus-vectored RSV vaccine not inhibited by maternal immunity

    Amount: $589,058.00

    DESCRIPTION (provided by applicant): RSV is the leading viral cause of lower respiratory illness and hospitalization in young children, yet there isn't an approved vaccine. The vast majority of c ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. Pre-erythrocytic Stage Antigen Discovery for Malaria Vaccine Development

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The development of an effective malaria vaccine is a high global health priority. Malaria is the most burdensome parasitic disease of man, exacting an estimated to ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Development of an Ad14 Vaccine

    Amount: $500,313.00

    DESCRIPTION (provided by applicant): Recent reports indicate that a new strain of adenovirus serotype 14 (Ad14) is causing frequent acute respiratory disease (ARD) and deaths in otherwise health peopl ...

    SBIR Phase I 2009 Department of Health and Human Services
  4. Development of Novel Alternative Serotype Adenoviral Vectors for Gene Delivery in

    Amount: $138,699.00

    DESCRIPTION (provided by applicant): Myriad studies have examined the potential of gene therapy in the inner ear. For the most part they have focused on adenoviral vectors and delivery into the cochl ...

    SBIR Phase I 2009 Department of Health and Human Services
  5. Production of Adenovector Based Vaccines

    Amount: $2,470,960.00

    DESCRIPTION (provided by applicant): Adenovirus vectors (Advectors) designed to express an antigenic gene have shown great promise as vaccines. Although GenVec and other groups have constructed numero ...

    SBIR Phase II 2009 Department of Health and Human Services
  6. Local Therapy-A Novel Approach to Cancer Metastases

    Amount: $295,991.00

    DESCRIPTION (provided by applicant): Metastases are the leading cause of death of most cancer patients. Leveraging the immune system to eliminate micrometastasis has long been attempted with only mode ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. High Throughput Genomics Screening for Malaria Antigen Discovery

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Malaria is a major threat to world health. Each year, there are 350-500 million clinical cases and greater than one million deaths due to malaria, primarily of chi ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Preclinical Testing of an Adenoviral Vector based HSV-2 Vaccine

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This proposal will leverage the expertise in HSV-2 and cellular immunology developed at the UW/FHCRC with the state of the art adenovirus delivery platform develop ...

    SBIR Phase I 2008 Department of Health and Human Services
  9. Adenovirus Vectors for Respiratory Syncytial Virus Vaccination

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory illness and hospitalization in young children and has long been recognized as a p ...

    SBIR Phase I 2008 Department of Health and Human Services
  10. Novel Ad5 Malaria Vaccine That Circumvents Pre-existing Ad5 Immunity

    Amount: $599,549.00

    DESCRIPTION (provided by applicant): Malaria is the most devastating parasitic disease affecting humans. Each year, there are 350-500 million clinical cases and greater than one million deaths due t ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government